[{"notes_id":"1_503","category":"4","subcategory":"1","title":"Non-alcoholic fatty liver disease","body":"Non-alcoholic fatty liver disease (NAFLD) is now the most common cause of liver disease in the developed world. It is largely caused by obesity and describes a spectrum of disease ranging from:<br \/><ul><li>steatosis - fat in the liver<\/li><li>steatohepatitis - fat with inflammation, non-alcoholic steatohepatitis (NASH), see below<\/li><li>progressive disease may cause fibrosis and liver cirrhosis<\/li><\/ul><br \/>NAFLD is thought to represent the hepatic manifestation of the metabolic syndrome and hence <span class=\"concept\" data-cid=\"721\">insulin resistance<\/span> is thought to be the key mechanism leading to steatosis.<br \/><br \/>Non-alcoholic steatohepatitis (NASH) is a term used to describe liver changes similar to those seen in alcoholic hepatitis in the absence of a history of alcohol abuse. It is relatively common and thought to affect around 3-4% of the general population. The progression of disease in patients with NASH may be responsible for a proportion of patients previously labelled as cryptogenic cirrhosis.<br \/><br \/>Associated factors<br \/><ul><li><span class=\"concept\" data-cid=\"11101\">obesity<\/span><\/li><li><span class=\"concept\" data-cid=\"721\">type 2 diabetes mellitus<\/span><\/li><li>hyperlipidaemia<\/li><li>jejunoileal bypass<\/li><li><span class=\"concept\" data-cid=\"4462\">sudden weight loss\/starvation<\/span><\/li><\/ul><br \/>Features<br \/><ul><li>usually asymptomatic<\/li><li>hepatomegaly<\/li><li><span class=\"concept\" data-cid=\"3981\">ALT is typically greater than AST<\/span><\/li><li>increased echogenicity on ultrasound<\/li><\/ul><br \/>NICE produced guidelines on the investigation and management of NAFLD in 2016. Key points:<br \/><ul><li>there is no evidence to support screening for NAFLD in adults, even in at risk groups (e.g. type 2 diabetes)<\/li><li>the guidelines are therefore based on the management of the <i>incidental<\/i> finding of NAFLD - typically asymptomatic fatty changes on liver ultrasound<\/li><li>in these patients, NICE recommends the use of the <span class=\"concept\" data-cid=\"8322\">enhanced liver fibrosis (ELF)<\/span> blood test to check for advanced fibrosis<\/li><li>the ELF blood test is a combination of hyaluronic acid + procollagen III + tissue inhibitor of metalloproteinase 1. An algorithm based on these values results in an ELF blood test score, similar to triple testing for Down's syndrome<\/li><\/ul><br \/>An excellent review by Byrne et Al<sup>1<\/sup> in 2018 reviewed the diagnosis and monitoring of NAFLD. It made the following suggestions if the ELF blood test was not available:<br \/><ul><li>non-invasive tests may be used to assess the severity of fibrosis<\/li><li>these include the FIB4 score or NALFD fibrosis score<\/li><li>these scores may be used in combination with a FibroScan (liver stiffness measurement assessed with transient elastography)<\/li><li>this combination has been shown to have excellent accuracy in predicting fibrosis<\/li><\/ul><br \/>Patients who are likely to have advanced fibrosis should be referred to a liver specialist. They will then likely have a liver biopsy to stage the disease more accurately.<br \/><br \/>Management<br \/><ul><li>the mainstay of treatment is lifestyle changes (particularly <span class=\"concept\" data-cid=\"3604\">weight loss<\/span>) and monitoring<\/li><li>there is ongoing research into the role of gastric banding and insulin-sensitising drugs (e.g. metformin, <span class=\"concept\" data-cid=\"1538\">pioglitazone<\/span>)<\/li><\/ul><br \/><b>References<\/b><br \/>1. BMJ 2018;362:k2734","notes_hash":"d4be84bc5e5eebcf4269bd7fa71cb0f6","knowledge_graph_node_id_link":1195,"links":"<table style='width:100%'><tr><td>NICE<\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1206\" data-linkid=\"1206\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"link_good_count_1206\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">14<\/span><button type=\"button\" style=\"\" id=\"link_dislike_1206\" data-linkid=\"1206\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"link_bad_count_1206\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">14<\/span><\/td><\/tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https:\/\/www.nice.org.uk\/guidance\/ng49\/chapter\/Recommendations\">2016 Non-alcoholic fatty liver disease (NAFLD): assessment and management<\/a><\/td><\/tr><\/table>","media":"<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/lGP9hNk64tg\" data-description=\"Understanding Non-Alcoholic Fatty Liver Disease\" data-upvotes=\"2\" data-downvotes=\"0\" data-media=\"1500\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/i1.ytimg.com\/vi\/lGP9hNk64tg\/mqdefault.jpg\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/www.youtube.com\/embed\/lGP9hNk64tg\" data-description=\"Understanding Non-Alcoholic Fatty Liver Disease\" data-upvotes=\"2\" data-downvotes=\"0\" data-media=\"1500\">Understanding Non-Alcoholic Fatty Liver Disease<\/a><\/td><\/tr><tr><td><span ><small>Zero To Finals - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2643\" data-mediaid=\"2643\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_2643\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">2<\/span><button type=\"button\" style=\"\" id=\"media_dislike_2643\" data-mediaid=\"2643\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_2643\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">0<\/span><\/td><\/tr><tr><td>&nbsp;<\/td><\/tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/0\/05\/Non-alcoholic_fatty_liver_disease.webm\" data-description=\"Non-alcoholic fatty liver disease (NAFLD) - causes, symptoms, diagnosis, treatment, pathology\" data-upvotes=\"4\" data-downvotes=\"4\" data-media=\"22\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https:\/\/d32xxyeh8kfs8k.cloudfront.net\/css\/images\/osmosis.png\" style=\"max-width:150px;\"><\/a><\/td><\/tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/0\/05\/Non-alcoholic_fatty_liver_disease.webm\" data-description=\"Non-alcoholic fatty liver disease (NAFLD) - causes, symptoms, diagnosis, treatment, pathology\" data-upvotes=\"4\" data-downvotes=\"4\" data-media=\"22\">Non-alcoholic fatty liver disease (NAFLD) - causes, symptoms, diagnosis, treatment, pathology<\/a><\/td><\/tr><tr><td><span ><small>Osmosis - YouTube<\/small><\/span><\/td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_45\" data-mediaid=\"45\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"\/><\/svg><\/button><span id=\"media_good_count_45\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">4<\/span><button type=\"button\" style=\"\" id=\"media_dislike_45\" data-mediaid=\"45\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"\/><\/svg><\/button><span id=\"media_bad_count_45\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">4<\/span><\/td><\/tr><\/table>","concepts_for_notes":{"721":{"concept_text":"T2DM with abnormal LFTs - ? non-alcoholic fatty liver disease","concept_percentile":"72"},"3604":{"concept_text":"Weight loss is the best first line management for NAFLD","concept_percentile":"55"},"8322":{"concept_text":"In patients with non-alcoholic fatty liver disease, enhanced liver fibrosis (ELF) testing is recommended to aid diagnosis of liver fibrosis","concept_percentile":"74"},"11101":{"concept_text":"Obesity with abnormal LFTs - ? non-alcoholic fatty liver disease","concept_percentile":"81"}},"category_name":"Gastroenterology \/ Nutrition","subcategory_name":"Gastroenterology \/ Nutrition","comment_count":4},"",[]]